Literature DB >> 33578800

Inflammatory Mechanisms Underlying Nonalcoholic Steatohepatitis and the Transition to Hepatocellular Carcinoma.

Moritz Peiseler1,2,3, Frank Tacke1.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a rising chronic liver disease and comprises a spectrum from simple steatosis to nonalcoholic steatohepatitis (NASH) to end-stage cirrhosis and risk of hepatocellular carcinoma (HCC). The pathogenesis of NAFLD is multifactorial, but inflammation is considered the key element of disease progression. The liver harbors an abundance of resident immune cells, that in concert with recruited immune cells, orchestrate steatohepatitis. While inflammatory processes drive fibrosis and disease progression in NASH, fueling the ground for HCC development, immunity also exerts antitumor activities. Furthermore, immunotherapy is a promising new treatment of HCC, warranting a more detailed understanding of inflammatory mechanisms underlying the progression of NASH and transition to HCC. Novel methodologies such as single-cell sequencing, genetic fate mapping, and intravital microscopy have unraveled complex mechanisms behind immune-mediated liver injury. In this review, we highlight some of the emerging paradigms, including macrophage heterogeneity, contributions of nonclassical immune cells, the role of the adaptive immune system, interorgan crosstalk with adipose tissue and gut microbiota. Furthermore, we summarize recent advances in preclinical and clinical studies aimed at modulating the inflammatory cascade and discuss how these novel therapeutic avenues may help in preventing or combating NAFLD-associated HCC.

Entities:  

Keywords:  cancer immunotherapy; hepatocellular carcinoma; inflammation; innate immunity; macrophages; nonalcoholic steatohepatitis

Year:  2021        PMID: 33578800      PMCID: PMC7916589          DOI: 10.3390/cancers13040730

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  258 in total

1.  Endogenous bile acids as carcinogens.

Authors:  Peter L M Jansen
Journal:  J Hepatol       Date:  2007-06-14       Impact factor: 25.083

2.  Neutrophil depletion improves diet-induced non-alcoholic fatty liver disease in mice.

Authors:  Rongying Ou; Jia Liu; Mingfen Lv; Jingying Wang; Jinmeng Wang; Li Zhu; Liang Zhao; Yunsheng Xu
Journal:  Endocrine       Date:  2017-04-06       Impact factor: 3.633

3.  Knockout of neutrophil elastase protects against western diet induced nonalcoholic steatohepatitis in mice by regulating hepatic ceramides metabolism.

Authors:  Jin Chen; Bingtian Liang; Dongxue Bian; Yan Luo; Jing Yang; Zhihui Li; Zhengjie Zhuang; Shufei Zang; Junping Shi
Journal:  Biochem Biophys Res Commun       Date:  2019-08-28       Impact factor: 3.575

4.  Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease.

Authors:  Rohit Loomba; Victor Seguritan; Weizhong Li; Tao Long; Niels Klitgord; Archana Bhatt; Parambir Singh Dulai; Cyrielle Caussy; Richele Bettencourt; Sarah K Highlander; Marcus B Jones; Claude B Sirlin; Bernd Schnabl; Lauren Brinkac; Nicholas Schork; Chi-Hua Chen; David A Brenner; William Biggs; Shibu Yooseph; J Craig Venter; Karen E Nelson
Journal:  Cell Metab       Date:  2017-05-02       Impact factor: 27.287

5.  Amelioration of non-alcoholic steatohepatitis and glucose intolerance in ob/ob mice by oral immune regulation towards liver-extracted proteins is associated with elevated intrahepatic NKT lymphocytes and serum IL-10 levels.

Authors:  Eran Elinav; Orit Pappo; Miriam Sklair-Levy; Maya Margalit; Oren Shibolet; Moshe Gomori; Roslana Alper; Barbara Thalenfeld; Dean Engelhardt; Elazar Rabbani; Yaron Ilan
Journal:  J Pathol       Date:  2006-01       Impact factor: 7.996

6.  Loss of Junctional Adhesion Molecule A Promotes Severe Steatohepatitis in Mice on a Diet High in Saturated Fat, Fructose, and Cholesterol.

Authors:  Khalidur Rahman; Chirayu Desai; Smita S Iyer; Natalie E Thorn; Pradeep Kumar; Yunshan Liu; Tekla Smith; Andrew S Neish; Hongliang Li; Shiyun Tan; Pengbo Wu; Xiaoxiong Liu; Yuanjie Yu; Alton B Farris; Asma Nusrat; Charles A Parkos; Frank A Anania
Journal:  Gastroenterology       Date:  2016-06-21       Impact factor: 22.682

7.  Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity.

Authors:  Jorge Henao-Mejia; Eran Elinav; Chengcheng Jin; Liming Hao; Wajahat Z Mehal; Till Strowig; Christoph A Thaiss; Andrew L Kau; Stephanie C Eisenbarth; Michael J Jurczak; Joao-Paulo Camporez; Gerald I Shulman; Jeffrey I Gordon; Hal M Hoffman; Richard A Flavell
Journal:  Nature       Date:  2012-02-01       Impact factor: 49.962

8.  Resveratrol ameliorates fibrosis and inflammation in a mouse model of nonalcoholic steatohepatitis.

Authors:  Takaomi Kessoku; Kento Imajo; Yasushi Honda; Takayuki Kato; Yuji Ogawa; Wataru Tomeno; Shingo Kato; Hironori Mawatari; Koji Fujita; Masato Yoneda; Yoji Nagashima; Satoru Saito; Koichiro Wada; Atsushi Nakajima
Journal:  Sci Rep       Date:  2016-02-25       Impact factor: 4.379

9.  Perivascular localization of macrophages in the intestinal mucosa is regulated by Nr4a1 and the microbiome.

Authors:  Masaki Honda; Bas G J Surewaard; Mayuki Watanabe; Catherine C Hedrick; Woo-Yong Lee; Kirsty Brown; Kathy D McCoy; Paul Kubes
Journal:  Nat Commun       Date:  2020-03-12       Impact factor: 14.919

10.  Steatohepatitis Impairs T-cell-Directed Immunotherapies Against Liver Tumors in Mice.

Authors:  Bernd Heinrich; Zachary J Brown; Laurence P Diggs; Mathias Vormehr; Chi Ma; Varun Subramanyam; Umberto Rosato; Benjamin Ruf; Juliane S Walz; John C McVey; Simon Wabitsch; Qiong Fu; Su Jong Yu; Qianfei Zhang; Chunwei W Lai; Ugur Sahin; Tim F Greten
Journal:  Gastroenterology       Date:  2020-10-01       Impact factor: 22.682

View more
  9 in total

1.  TAZ-induced Cybb contributes to liver tumor formation in non-alcoholic steatohepatitis.

Authors:  Xiaobo Wang; Sharon Zeldin; Hongxue Shi; Changyu Zhu; Yoshinobu Saito; Kathleen E Corey; Stephanie A Osganian; Helen E Remotti; Elizabeth C Verna; Utpal B Pajvani; Robert F Schwabe; Ira Tabas
Journal:  J Hepatol       Date:  2021-12-11       Impact factor: 30.083

2.  The role of NK cells in oncolytic viral therapy: a focus on hepatocellular carcinoma.

Authors:  Frazer Warricker; Salim I Khakoo; Matthew D Blunt
Journal:  J Transl Genet Genom       Date:  2021-08-04

Review 3.  PD-1/PD-L1 Immuno-Mediated Therapy in NAFLD: Advantages and Obstacles in the Treatment of Advanced Disease.

Authors:  Rosa Lombardi; Roberto Piciotti; Paola Dongiovanni; Marica Meroni; Silvia Fargion; Anna Ludovica Fracanzani
Journal:  Int J Mol Sci       Date:  2022-02-28       Impact factor: 5.923

Review 4.  Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease.

Authors:  Tobias Puengel; Hanyang Liu; Adrien Guillot; Felix Heymann; Frank Tacke; Moritz Peiseler
Journal:  Int J Mol Sci       Date:  2022-02-28       Impact factor: 5.923

Review 5.  Pathogenesis from Inflammation to Cancer in NASH-Derived HCC.

Authors:  Simiao Yu; Jingxiao Wang; Haocheng Zheng; Ruilin Wang; Nadia Johnson; Tao Li; Ping Li; Jie Lin; Yuan Li; Jin Yan; Ying Zhang; Zhenyu Zhu; Xia Ding
Journal:  J Hepatocell Carcinoma       Date:  2022-08-26

Review 6.  Obesity Management in the Primary Prevention of Hepatocellular Carcinoma.

Authors:  Elizabeth R M Zunica; Elizabeth C Heintz; Christopher L Axelrod; John P Kirwan
Journal:  Cancers (Basel)       Date:  2022-08-22       Impact factor: 6.575

7.  Data mining of key genes expression in hepatocellular carcinoma: novel potential biomarkers of diagnosis prognosis or progression.

Authors:  Manuela Cabiati; Melania Gaggini; Paolo De Simone; Silvia Del Ry
Journal:  Clin Exp Metastasis       Date:  2022-04-16       Impact factor: 4.510

Review 8.  Inflammation and Fibrogenesis in MAFLD: Role of the Hepatic Immune System.

Authors:  Pietro Torre; Benedetta Maria Motta; Roberta Sciorio; Mario Masarone; Marcello Persico
Journal:  Front Med (Lausanne)       Date:  2021-12-09

Review 9.  Regression of Hepatic Fibrosis and Evolution of Cirrhosis: A Concise Review.

Authors:  Shahbaz Khan; Romil Saxena
Journal:  Adv Anat Pathol       Date:  2021-11-01       Impact factor: 3.875

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.